Following The Money: Institution’s Growing Stake In CorMedix Inc (NASDAQ: CRMD)

CorMedix Inc (CRMD) concluded trading on Wednesday at a closing price of $11.68, with 7.05 million shares of worth about $82.35 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.92% during that period and on May 07, 2025 the price saw a gain of about 4.66%. Currently the company’s common shares owned by public are about 67.71M shares, out of which, 59.59M shares are available for trading.

Stock saw a price change of 27.09% in past 5 days and over the past one month there was a price change of 92.42%. Year-to-date (YTD), CRMD shares are showing a performance of 44.20% which increased to 100.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.61 but also hit the highest price of $13.85 during that period. The average intraday trading volume for CorMedix Inc shares is 1.51 million. The stock is currently trading 35.75% above its 20-day simple moving average (SMA20), while that difference is up 32.18% for SMA50 and it goes to 33.29% higher than SMA200.

CorMedix Inc (NASDAQ: CRMD) currently have 67.71M outstanding shares and institutions hold larger chunk of about 35.67% of that.

The stock has a current market capitalization of $792.02M and its 3Y-monthly beta is at 1.54. PE ratio of stock for trailing 12 months is 51.82, while it has posted earnings per share of $0.23 in the same period. It has Quick Ratio of 3.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRMD, volatility over the week remained 10.36% while standing at 7.30% over the month.

Stock’s fiscal year EPS is expected to rise by 338.33% while it is estimated to increase by 102.80% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on March 07, 2025 offering an Outperform rating for the stock and assigned a target price of $18 to it. Coverage by D. Boral Capital stated CorMedix Inc (CRMD) stock as a Buy in their note to investors on January 13, 2025, suggesting a price target of $15 for the stock. On August 26, 2024, Rodman & Renshaw Initiated their recommendations, while on August 10, 2023, RBC Capital Mkts Initiated their ratings for the stock with a price target of $6. Stock get a Buy rating from Needham on February 17, 2021.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.